PML-RARalpha ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL

Leukemia. 2010 Feb;24(2):473-6. doi: 10.1038/leu.2009.220. Epub 2009 Oct 29.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Leukemia, Promyelocytic, Acute / genetics*
  • Leukemia, Promyelocytic, Acute / pathology
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / genetics
  • Neoplasm Recurrence, Local / pathology
  • Oncogene Proteins, Fusion / genetics*
  • Protein Structure, Tertiary
  • Sequence Deletion / genetics*
  • Treatment Outcome
  • Tretinoin / therapeutic use*

Substances

  • Antineoplastic Agents
  • Oncogene Proteins, Fusion
  • promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  • Tretinoin